Site Editor
William J. Gradishar, MD, FACP, FASCO
William J. Gradishar, MD, FACP, FASCO
Posted: Wednesday, November 30, 2022
Researchers have tested the effectiveness of the PARP inhibitor olaparib in combination with radiotherapy for high-risk individuals diagnosed with early-stage triple-negative breast cancer. In the phase I RADIOPARP trial, they sought to identify the maximum tolerated dose of olaparib in combination with radiotherapy in this patient population. These findings were presented by Pierre Loap, MD, MS, of the Institut Curie, Paris, and colleagues at the American Society for Radiation Oncology (ASTRO) 2022 Annual Meeting (Abstract 173).
This study included 24 patients with triple-negative breast cancer who started olaparib 7 days prior to irradiation and continued to receive the agent throughout treatment. “A time-to-event continual reassessment method was used to increase olaparib through four increasing dose levels (50 mg, 100 mg, 150 mg, or 200 mg twice a day) with a 25% maximum probability rate of dose-limiting toxicities,” the investigators reported.
The maximum tolerated dosage was not reached at 200 mg of olaparib twice daily; this is the dosage Dr. Loap and colleagues recommend for future trials of this combination therapy. In addition, with a median follow-up of 34 months, no late treatment-related grade ≥ 3 toxicity was observed. Grade 2 toxicities were observed for breast pain, fibrosis, deformity, and telangiectasia. In terms of efficacy, the 3-year overall survival and event-free survival rates were 83% [95% confidence interval = 70%–100%] and 68% [95% confidence interval = 51%–91%], respectively. Homologous recombination proficiency status was not associated with survival outcomes.
Disclosure: Dr. Loap reported no conflicts of interest.
JNCCN Spotlights
Resources
For your Patients
